Skip to main content
TipRanks
Go Ultimate75% OFF

Kintor Pharmaceutical Ltd (9939) AI Stock Analysis

3 Followers
HK:9939

Kintor Pharmaceutical Ltd

(HKEX:9939)

Select Model
Rating:37Underperform
Price Target:HKD 1.00â–¼(-31.03% Downside)
Action:downgraded
Date:11/03/26

The stock scores at the bottom of the range due to severe fundamental and technical headwinds. The most significant factor is the company's precarious financial state, marked by massive losses and a high cash burn rate that threatens its viability without additional capital. This is compounded by a bearish technical trend with the stock price in a sustained downtrend below all major moving averages. The negative P/E ratio further confirms a lack of current earnings power.

Positive Factors
Revenue ReboundThe 2025 revenue rebound indicates that the company is generating more commercial activity than in the prior year. If this improvement persists, a larger revenue base could support better operating leverage and provide a stronger foundation for funding development and commercialization.
Negative Factors
Persistent UnprofitabilityNegative gross profit means the current revenue base does not cover direct costs, before broader research and operating expenses are considered. Persistent operating and net losses indicate that commercialization has not yet produced a sustainable earnings model.

Kintor Pharmaceutical Ltd (9939) vs. iShares MSCI Hong Kong ETF (EWH)

-50%-25%0%25%50%75%100%125%HK:9939-30.62%EWH+9.24%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 652.68M
Dividend Yield
―
Average Volume (3M)
934.05K
Price to Earnings (P/E)
-2.8
Beta (1Y)
1.17
Revenue Growth
647.17%
EPS Growth
-8.86%
Country
Hong Kong
Employees
122
Sector
General
Sector Strength
55
Industry
Biotechnology

Kintor Pharmaceutical Ltd Business Overview & Revenue Model

Company Description

Kintor Pharmaceutical Limited, a biotechnology firm in its clinical development phase, is dedicated to the discovery, advancement, and marketing of a diverse array of small molecule and biological therapies. The company primarily concentrates on andr...

How the Company Makes Money

Kintor Pharmaceutical Ltd’s business model is typical of a clinical-stage biopharmaceutical developer: it invests in R&D to advance proprietary drug candidates and seeks to monetize them primarily through (i) out-licensing and collaboration arrangeme...

Kintor Pharmaceutical Ltd Financial Statement Overview

Summary

Financial health is critically weak. While revenue grew 169%, the company is deeply unprofitable with a -612% net margin and -$166M free cash flow. Equity is eroding rapidly (-38% YoY), and the cash burn rate, though improved, remains unsustainable without new financing.

Income Statement

28Negative

Balance Sheet

35Negative

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue77.57M32.68M5.00M0034.23M
Gross Profit9.75M8.04M-4.73M-67.63M-21.38M34.23M
EBITDA-159.18M-139.23M-128.37M-1.05B-950.74M-829.09M
Net Income-189.63M-200.11M-155.29M-1.06B-954.37M-842.10M
Balance Sheet
Total Assets318.88M340.95M515.13M869.23M2.06B2.07B
Cash, Cash Equivalents and Short-Term Investments31.79M34.78M148.69M455.50M875.08M1.06B
Total Debt133.56M86.64M133.01M253.92M286.39M159.73M
Total Liabilities209.68M158.28M221.05M411.12M559.95M412.83M
Stockholders Equity109.20M182.67M294.08M458.11M1.50B1.66B
Cash Flow
Free Cash Flow-99.68M-166.07M-200.76M-390.30M-988.73K-1.13M
Operating Cash Flow-149.83M-165.34M-199.08M-387.58M-961.26K-1.05M
Investing Cash Flow267.76K14.04M20.03M3.27M67.19K92.00K
Financing Cash Flow126.54M39.23M-119.67M-33.46M815.75K857.42K

Kintor Pharmaceutical Ltd Technical Analysis

Technical Analysis SentimentNegative
Last Price1.45

Price Trends

50DMA1.64Negative
100DMA1.72Negative
200DMA2.26Negative

Market Momentum

MACD-0.08Negative
RSI38.71Neutral
STOCH40.53Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9939, the sentiment is Negative. The current price of 1.45 is above the 20-day moving average (MA) of 1.42, below the 50-day MA of 1.64, and below the 200-day MA of 2.26, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 38.71 is Neutral, neither overbought nor oversold. The STOCH value of 40.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9939.

Kintor Pharmaceutical Ltd Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

HK:9939 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
HK:1244HK:124452NeutralHKD 662.22M-3.07-30.93%―-17.22%-6.13%
HK:6855HK:685550NeutralHKD 9.72B-5.71-153.78%―70.26%-12.79%
HK:1167HK:116748NeutralHKD 3.27B5.4347.76%―286.20%―
HK:2171HK:217139UnderperformHKD 5.96B-53.05-9.45%―68.12%81.84%
HK:9966HK:996639UnderperformHKD 5.52B-27.95-10.27%―-31.77%-177.01%
HK:9939HK:993937UnderperformHKD 653.62M-2.75-129.93%―647.17%-8.86%

* General Sector Average

Performance Comparison

-50%0%50%100%HK:9939HK:9966HK:1167HK:1244HK:2171HK:6855Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:9939 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:9939Kintor Pharmaceutical Ltd1.45-0.62-29.95%
HK:9966Alphamab Oncology5.47-4.72-46.32%
HK:1167Jacobio Pharmaceuticals Group Co., Ltd.4.07-2.54-38.50%
HK:12443D Medicines, Inc.2.50-2.63-51.36%
HK:2171CARsgen Therapeutics Holdings Ltd.10.45-6.86-39.63%
HK:6855Ascentage Pharma Group International25.62-37.68-59.53%

Kintor Pharmaceutical Ltd Corporate Events

Kintor Completes Long-Term Safety Trial for KX-826 in China

Nov 2, 2026

Kintor Pharmaceutical said it completed follow-up visits in a one-year, long-term safety trial of KX-826 tincture 1.0% for male androgenetic alopecia in China, with favorable safety results. The multicenter, open-label study covered 12 Chinese resear...

Kintor Steps Up Cash-Flow Measures as KX-826 and KOSHINÉ Drive Growth

Oct 30, 2026

Kintor Pharmaceutical has outlined progress on measures to resolve a prior auditor’s disclaimer of opinion linked to going-concern uncertainties, focusing on improving operating cash flow and strengthening its financial position. The company is pursu...

Kintor Wins China Patent for Core Skin-Whitening Ingredient KT-939

Oct 21, 2026

Kintor Pharmaceutical has received a notice of grant of an invention patent in China for KT-939, its in-house developed tyrosinase inhibitor aimed at inhibiting melanin production. The patent covers both the specific chemical structure and broader co...

Kintor Pharma Reshapes Finance Leadership With New CFO and Process Agent

Sep 21, 2026

Kintor Pharmaceutical Limited announced that chief financial officer and joint company secretary Ming Ming Cheung has resigned, also stepping down as the company’s Hong Kong process agent, effective 21 September 2026. The board emphasized that Cheung...

Kintor completes year-long safety trial for whitening ingredient KT-939

Sep 6, 2026

Kintor Pharmaceutical announced the successful completion of a year-long human safety trial for KT-939, its in-house developed tyrosinase inhibitor designed for whitening and freckle-removal cosmetic applications. The open-label study followed 114 su...

Kintor Pharmaceutical Boosts Revenue on Cosmetics Push but Stays in the Red

Aug 19, 2026

Kintor Pharmaceutical reported a sharp increase in revenue to RMB52.0 million for the six months ended June 30, 2026, up from RMB6.0 million a year earlier, driven mainly by global sales of its new high-end cosmetics brand KOSHINÉ that uses core prod...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 03, 2026